[DOI] [PubMed] [Google Scholar] 148.Rubino D., Abrahamsson N., Davies M., Hesse D., Greenway F.L., Jensen C., Lingvay I., Mosenzon O., Rosenstock J., Rubio M.A., et al
Ethical & Transparent Practices Avoid false claims, protect privacy, maintain professionalism
Studies have shown that it can lead to significant weight reduction in people who are overweight or have obesity
Este frmaco es un agonista del receptor del pptido similar al glucagn tipo 1 (arGLP-1) eficaz, dados sus confirmados efectos sobre la reduccin de la glucosa y la prdida de peso, demostrados en los ensayos clnicos aleatorizados y confirmados en los ensayos en vida real en poblacin no seleccionada
The SELECT trial, completed in 2023 with over 17,600 participants, showed a 20% reduction in cardiovascular events in patients with established cardiovascular disease and overweight or obesity without diabetes